AR111776A1 - Heteroarilos inhibidores de las proteínas ras mutantes de g12c - Google Patents

Heteroarilos inhibidores de las proteínas ras mutantes de g12c

Info

Publication number
AR111776A1
AR111776A1 ARP180101198A ARP180101198A AR111776A1 AR 111776 A1 AR111776 A1 AR 111776A1 AR P180101198 A ARP180101198 A AR P180101198A AR P180101198 A ARP180101198 A AR P180101198A AR 111776 A1 AR111776 A1 AR 111776A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
hydroxy
heteroaryl
alkoxy
Prior art date
Application number
ARP180101198A
Other languages
English (en)
Spanish (es)
Inventor
Piotr Antoni Raubo
Graeme Richard Rob
Shaun Michael Fillery
Andrew John Eatherton
Scott Boyd
Sharanjeet Kaur Bagal
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR111776A1 publication Critical patent/AR111776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP180101198A 2017-05-11 2018-05-08 Heteroarilos inhibidores de las proteínas ras mutantes de g12c AR111776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762504638P 2017-05-11 2017-05-11

Publications (1)

Publication Number Publication Date
AR111776A1 true AR111776A1 (es) 2019-08-21

Family

ID=62492577

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101198A AR111776A1 (es) 2017-05-11 2018-05-08 Heteroarilos inhibidores de las proteínas ras mutantes de g12c

Country Status (8)

Country Link
US (2) US20200109153A1 (https=)
EP (1) EP3621968A1 (https=)
JP (1) JP2020519589A (https=)
CN (1) CN110603258A (https=)
AR (1) AR111776A1 (https=)
CA (1) CA3061650A1 (https=)
TW (1) TW201906848A (https=)
WO (1) WO2018206539A1 (https=)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842433B1 (en) 2018-01-19 2023-11-01 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US20220152026A1 (en) 2019-02-12 2022-05-19 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
KR102934231B1 (ko) 2019-03-05 2026-03-06 아스트라제네카 아베 항암제로 유용한 융합 삼환식 화합물
KR20220012255A (ko) * 2019-04-28 2022-02-03 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용
US12421236B2 (en) 2019-06-25 2025-09-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
JP7756069B6 (ja) * 2019-08-02 2025-11-27 上海済▲ユウ▼医薬科技股▲フン▼有限公司 四環式化合物、その調製と使用の方法
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
WO2021052499A1 (zh) * 2019-09-20 2021-03-25 上海济煜医药科技有限公司 稠合吡啶酮类化合物及其制备方法和应用
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
WO2021063346A1 (zh) * 2019-09-30 2021-04-08 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
CN112745335B (zh) * 2019-10-30 2024-08-30 武汉誉祥医药科技有限公司 一种三并杂环化合物及其用途
AU2020372700A1 (en) 2019-11-01 2022-05-12 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
PT3886991T (pt) * 2019-12-11 2022-10-17 Lilly Co Eli Inibidores de kras g12c
CN111039845A (zh) * 2019-12-18 2020-04-21 大连奇凯医药科技有限公司 一种4-氟-7-溴靛红的制备方法
CN114761408B (zh) * 2019-12-19 2023-09-15 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2021197499A1 (zh) * 2020-04-03 2021-10-07 南京明德新药研发有限公司 八氢吡嗪并二氮杂萘啶二酮类化生物
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CN114075219B (zh) * 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
JP2023544450A (ja) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド 三環式ピリドン及びピリミドン
TWI880049B (zh) 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685531B (zh) * 2020-12-25 2024-10-22 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CA3210167A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CA3211725A1 (en) * 2021-03-17 2022-09-22 Tao Jiang Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
JP2024513881A (ja) * 2021-04-08 2024-03-27 ジェネンテック， インコーポレイテッド オキサゼピン化合物及びがんの治療におけるその使用
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
EP4361157A4 (en) * 2021-06-21 2024-10-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240024926A (ko) 2021-06-24 2024-02-26 신젠타 크롭 프로텍션 아게 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물
AU2022303440A1 (en) * 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR20240069725A (ko) 2021-09-22 2024-05-20 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 피리딘 유도체 및 이의 용도
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
MX2024004846A (es) 2021-10-22 2024-05-03 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
CN118176198A (zh) * 2021-11-01 2024-06-11 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN119212994A (zh) 2021-12-17 2024-12-27 建新公司 作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4486345A1 (en) 2022-03-04 2025-01-08 Eli Lilly and Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
AU2023231139A1 (en) 2022-03-11 2024-09-05 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
CR20240508A (es) * 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
JP2025520650A (ja) 2022-06-21 2025-07-03 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性な縮合二環式芳香族複素環式化合物
AU2023302139A1 (en) * 2022-07-05 2024-12-19 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AU2023314335A1 (en) * 2022-07-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising kras g12d inhibitor
IL318647A (en) * 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024032704A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2023320914A1 (en) * 2022-08-11 2025-02-27 Beone Medicines I Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
JP2025528126A (ja) * 2022-08-11 2025-08-26 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環式化合物、その組成物、及びそれらによる処置方法
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
AU2023363515A1 (en) * 2022-10-18 2025-04-17 Idience Co., Ltd. Novel triheterocyclic compounds
CN120659773A (zh) 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
CN115583937B (zh) * 2022-11-21 2023-05-02 北京志道生物科技有限公司 以吲哚或氮杂吲哚为母核的kras抑制剂及其制备方法
WO2024110554A1 (en) 2022-11-23 2024-05-30 Syngenta Crop Protection Ag N-[(1 -[2-[6-(pyridazin-3-yl]-1,2,4-triazol-3-yl]ethyl]-quinazolin-4-amine and n-[1-[3-(6-(pyridazin-3-yl)pyrazin-2-yl]ethyl]-8-quinazolin-4-amine derivatives as pesticides
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof
AU2023388747A1 (en) * 2022-12-07 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused cyclic compounds and use thereof
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024153119A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN120957997A (zh) * 2023-04-21 2025-11-14 江苏恒瑞医药股份有限公司 一种含氮四环化合物的结晶形式及其制备方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024230734A1 (en) * 2023-05-08 2024-11-14 Jacobio Pharmaceuticals Co., Ltd. K-ras inhibitors and use thereof
WO2024243186A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
CN121263417A (zh) 2023-06-30 2026-01-02 金橘生物科技公司 取代的稠合三环胺化合物及其作为ras抑制剂的用途
WO2025022007A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025022008A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025132349A1 (en) 2023-12-19 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025132754A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4691041B2 (ja) * 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
WO2011121350A1 (en) * 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
AU2014229283B2 (en) * 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins

Also Published As

Publication number Publication date
US20220127281A1 (en) 2022-04-28
EP3621968A1 (en) 2020-03-18
CN110603258A (zh) 2019-12-20
JP2020519589A (ja) 2020-07-02
TW201906848A (zh) 2019-02-16
WO2018206539A1 (en) 2018-11-15
CA3061650A1 (en) 2018-11-15
US20200109153A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
AR111776A1 (es) Heteroarilos inhibidores de las proteínas ras mutantes de g12c
AR113905A1 (es) Feniléteres herbicidas
AR114083A2 (es) AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
AR088989A1 (es) Derivados biciclicos de dihidroisoquinolin-1-ona
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
AR110227A2 (es) Derivados de pirazol con acción sobre fgf
AR124443A1 (es) Compuestos y composición para el tratamiento de condiciones asociadas con cgas
AR091464A1 (es) Compuestos biciclicos de tiofenilamida
AR098492A1 (es) Derivados de purina
AR097633A1 (es) Pesticidas de azol bicíclico sustituido con heterociclos
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR094684A1 (es) Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih
AR098475A1 (es) Compuestos pesticidas y usos
AR099936A1 (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
AR121913A1 (es) Compuestos terapéuticos
AR109304A1 (es) Compuesto de oxadiazol y su uso
AR113886A1 (es) Derivados de indol macrocíclicos
AR097950A1 (es) N-hetaril(tio)carbonil-2-(benzocicloalquen-1-il)ciclaminas
AR093796A1 (es) Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa
AR115898A1 (es) 1,7-naftiridinas como inhibidores de cdk8/19
AR102773A1 (es) Derivados de pirido benzodiazepina sustituidos y su utilización
AR089782A1 (es) Derivados heterociclicos biciclicos, su preparacion y su aplicacion en terapeutica
AR105360A1 (es) Hidrazidas de ácido carboxílico heteroarilo sustituidas o sus sales y su uso para aumentar la tolerancia al estrés en plantas
AR105324A1 (es) Hidrazidas de ácido carboxílico arilo y heteroarilo cíclicas sustituidas o sus sales y su uso para aumentar la tolerancia al estrés en plantas

Legal Events

Date Code Title Description
FB Suspension of granting procedure